In the BioHarmony Drug Report Database

"Preview" Icon

Istradefylline

Nourianz (istradefylline) is a small molecule pharmaceutical. Istradefylline was first approved as Nourianz on 2019-08-27. It is used to treat parkinson disease in the USA. It is known to target adenosine receptor A2b, adenosine receptor A3, adenosine receptor A2a, and adenosine receptor A1. Nourianz’s patents are valid until 2027-09-05 (FDA).

 

Trade Name

 

Nourianz
 

Common Name

 

istradefylline
 

ChEMBL ID

 

CHEMBL431770
 

Indication

 

parkinson disease
 

Drug Class

 

Theophylline derivatives

Image (chem structure or protein)

Istradefylline structure rendering